| WU, Xiaohua |
FLAMES, NCT04169997: A Study of IMP4297 as Maintenance Treatment Following First-line Chemotherapy in Patients With Advanced Ovarian Cancer |
|
|
| Recruiting | 3 | 393 | RoW | IMP4927, Placebos | Impact Therapeutics, Inc. | Ovarian Cancer | 02/22 | 12/22 | | |
NCT05371301: Efficacy of Primary Debulking Surgery Versus Neoadjuvant Chemotherapy in Stage IV Ovarian Cancer |
|
|
| Recruiting | 3 | 200 | RoW | Paclitaxel, Carboplatin, debulking surgery | Fudan University | Ovarian Cancer | 12/22 | 12/23 | | |
NCT05622890: A Single-arm Clinical Trial of IMGN853 in Chinese Adult Patients With Platinum-resistant, Epithelial Ovarian Cancer |
|
|
| Recruiting | 3 | 35 | RoW | Mirvetuximab Soravtansine, IMGN853, MIRV | Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. | Epithelial Ovarian Cancer, Peritoneal Cancer, Fallopian Tube Cancer | 04/23 | 12/23 | | |
| Not yet recruiting | 3 | 420 | RoW | Anlotinib hydrochloride capsule + TQB2450 injection, Chemotherapy drug | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Endometrial Cancer | 12/27 | 06/29 | | |
| Active, not recruiting | 3 | 366 | RoW | Olaparib, Matching placebo | AstraZeneca | Ovarian Cancer | 04/25 | 04/26 | | |
|
|
NCT06584032: Study of Fruquintinib Plus Sintilimab for Treatment of Advanced Endometrial Cancer |
|
|
| Recruiting | 3 | 412 | RoW | fruquintinib, HMPL-013, sintilimab, IBI308, paclitaxel, doxorubicin | Hutchmed | Advanced Endometrial Cancer | 01/29 | 06/29 | | |
CHIPRO, NCT04921527: Chiauranib Plus Weekly Paclitaxel in Patients with Platinum-refractory or Platinum-resistant Recurrent Ovarian Cancer |
|
|
| Recruiting | 3 | 454 | RoW | chiauranib, CS2164, Placebo, Paclitaxel, Anzatax | Chipscreen Biosciences, Ltd. | Ovarian Cancer, Relapsed or Refractory, Chiauranib, Paclitaxel | 12/24 | 07/25 | | |
COMPASSION-16, NCT04982237: A Study of AK104 Plus Platinum-containing Chemotherapy±Bevacizumab as First-line Treatment for Persistent, Recurrent, or Metastatic Cervical Cancer |
|
|
| Recruiting | 3 | 440 | RoW | AK104, paclitaxel, carboplatin, cisplatin, bevacizumab, Placebo | Akeso | Cervical Cancer | 04/25 | 12/25 | | |
AK104-305, NCT05235516: A Study of AK104/Placebo Combined With Chemoradiotherapy For The Treatment of Locally Advanced Cervical Cancer |
|
|
| Active, not recruiting | 3 | 636 | RoW | AK104, EBRT, BT, cisplatin, Placebo | Akeso | Locally Advanced Cervical Carcinoma | 05/26 | 05/29 | | |
TQB2450-II-08, NCT04574284: A Study of TQB2450 Injection Combined With Anlotinib Hydrochloride Capsule in Subjects With Advanced Endometrial Cancer |
|
|
| Recruiting | 2 | 196 | RoW | TQB2450, Anlotinib | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Advanced Endometrial Cancer | 12/21 | 04/22 | | |
| Recruiting | 2 | 100 | RoW | IMP4297 | Impact Therapeutics, Inc. | Ovarian Cancer | 03/22 | 08/22 | | |
NCT03972722: Study of GLS-010 Injection in Patients With Recurrent or Metastatic Cervical Cancer |
|
|
| Recruiting | 2 | 89 | RoW | GLS-010, Full-human anti-pd-1 monoclonal antibodies | Guangzhou Gloria Biosciences Co., Ltd. | Cervical Cancer | 05/22 | 05/23 | | |
|
NCT04836663: A Study of TQ-B3525 Tablets in Subjects With PIK3CA and/or PIK3R1/2 Gene-altered Recurrent/Metastatic Advanced Gynecologic Tumors |
|
|
| Recruiting | 2 | 90 | RoW | TQ-B3525 tablet | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Advanced Endometrial Cancer, Cervical Cancer and Ovarian Cancer | 09/22 | 12/22 | | |
| Recruiting | 2 | 265 | RoW | SHR-1210, Camrelizumab, Famitinib, Famitinib Malate Capsule | Jiangsu HengRui Medicine Co., Ltd. | Renal Cell Carcinoma, Urothelial Carcinoma, Cervical Cancer, Ovarian Cancer Recurrent, Endometrial Cancer | 12/22 | 12/22 | | |
NCT05043922: A Study to Evaluate the Efficacy and Safety of CYH33 in Patients With Recurrent/Persistent Ovary Clear Cell Carcinoma |
|
|
| Recruiting | 2 | 86 | Japan, RoW | CYH33 | Haihe Biopharma Co., Ltd. | Ovarian Cancer, Recurrent Cancer | 06/23 | 06/23 | | |
NCT04593485: Anti-PD-1 Antibody in the Treatment of Patients With Malignant Melanoma of the Female Genital Tract |
|
|
| Recruiting | 2 | 40 | RoW | Camrelizumab for injection, Jiangsu Hengrui, SHR-1210 | Fudan University | Malignant Melanoma | 10/23 | 12/23 | | |
NCT02562365: Adjuvant Chemotherapy of Three-step Regimen in Ovarian Cancer |
|
|
| Active, not recruiting | 2 | 130 | RoW | Etoposide, Cyclophosphamide, Carboplatin, VP-16,CTX,CBP | Xiaohua Wu MD | Ovarian Cancer | 11/23 | 11/23 | | |
NCT05479487: Fluzoparib and Apatinib Versus Fluzoparib in Relapsed Ovarian Carcinoma Maintenance Treatment |
|
|
| Not yet recruiting | 2 | 132 | NA | Fluzoparib+Apatinib, Fluzoparib Monotherapy | Xiaohua Wu MD | Relapsed Ovarian Cancer | 11/23 | 09/26 | | |
NCT05112991: Study of Envafolimab Alone or With Lenvatinib in Patients With Advanced Endometrial Cancer |
|
|
| Recruiting | 2 | 108 | RoW | Envafolimab+Lenvatinib, Envafolimab | 3D Medicines (Sichuan) Co., Ltd. | Advanced Endometrial Cancer | 03/25 | 10/25 | | |
| Active, not recruiting | 2 | 56 | RoW | SHR-1316, Cisplatin Injection/Carboplatin Injection, External Beam Radiotherapy (EBRT)/Brachytherapy, Paclitaxel Injection | Shanghai Shengdi Pharmaceutical Co., Ltd | Locally Advanced Cervical Cancer | 12/24 | 01/25 | | |
NCT06241781: Autologous Tumor Infiltrating Lymphocytes (GT101 Injection) in Patients With Recurrent or Metastatic Cervical Cancer |
|
|
| Recruiting | 2 | 64 | RoW | GT101 injection, Gemcitabine injection | Grit Biotechnology | Adult | 01/27 | 01/27 | | |
| Recruiting | 2 | 70 | RoW | WX390, WXFL10030390 | Shanghai Jiatan Pharmatech Co., Ltd | Solid Tumor | 06/24 | 06/24 | | |
NCT06434610: A Study of B013 in Combination With Paclitaxel in Patients With Platinum-resistant Recurrent Ovarian Cancer. |
|
|
| Recruiting | 2 | 90 | RoW | B013, Paclitaxel, Placebo | Shanghai Jiaolian Drug Research and Development Co., Ltd, Shanghai Pharmaceuticals Holding Co., Ltd | Platinum-resistant Recurrent Ovarian Cancer | 12/26 | 12/26 | | |
| Recruiting | 2 | 240 | Europe, Canada, US, RoW | SKB264, Pembrolizumab, Keytruda | Klus Pharma Inc., Myriad Genetics, Inc., Discovery Life Sciences, LLC, Ventana Medical Systems, Inc, Frontage Laboratories, Inc. | Solid Tumor | 11/26 | 12/27 | | |
BGB-290-102, NCT03333915: Study of the Efficacy, Safety and Pharmacokinetics of Pamiparib (BGB-290) in Participants With Advanced Solid Tumors |
|
|
| Completed | 1/2 | 128 | RoW | Pamiparib, BGB-290 | BeiGene | Advanced High-grade Ovarian Cancer, Triple Negative Breast Cancer | 08/20 | 08/21 | | |
|
|
|
|
|
| Recruiting | 1/2 | 18 | RoW | TC-E202 cells, TCR T Cells, IL-2, Fludarabine, Cyclophosphamide Capsules | TCRCure Biopharma Ltd., Fudan University | Cervical Carcinoma | 12/24 | 08/25 | | |
NCT06682780: A Phase I/II Study of LM-2417 in Subjects With Advanced Solid Tumours |
|
|
| Not yet recruiting | 1/2 | 320 | RoW | LM-2417, Docetaxel, Toripalimab/Tirelizumab, Carboplatin, Niraparib, Lenvatinib | LaNova Medicines Limited | Advanced Solid Tumor | 12/27 | 12/29 | | |
| Recruiting | 1/2 | 725 | RoW | JSKN003 | Jiangsu Alphamab Biopharmaceuticals Co., Ltd | Advanced Solid Tumor | 12/24 | 12/26 | | |
|
| Recruiting | 1/2 | 404 | US, RoW | Rina-S, PRO1184, Rinatabart sesutecan, GEN1184, Carboplatin, Bevacizumab, Pembrolizumab | Genmab | Platinum-Resistant Ovarian Cancer, Platinum Sensitive Ovarian Cancer (PSOC), High Grade Epithelial Ovarian Cancer, High Grade Serous Ovarian Cancer, Primary Peritoneal Carcinoma, Fallopian Tube Cancer, Endometrial Cancer, Non-small Cell Lung Cancer, Epidermal Growth Factor Receptor (EGFR)-Mutated Non-Small Cell Lung Cancer (NSCLC), Mesothelioma, Breast Adenocarcinoma, Triple Negative Breast Cancer, Hormone Receptor-positive/Her2 Negative Breast Cancer | 04/26 | 10/26 | | |
| Not yet recruiting | 1/2 | 208 | RoW | SHR-4375 | Suzhou Suncadia Biopharmaceuticals Co., Ltd. | Solid Tumors | 05/27 | 05/27 | | |
NCT06770881: JSKN033 in Chinese Subjects with Advanced Malignant Tumors |
|
|
| Not yet recruiting | 1/2 | 430 | NA | JSKN033 | Jiangsu Alphamab Biopharmaceuticals Co., Ltd | Advanced Malignant Tumors | 12/26 | 12/27 | | |
NCT05803018: A Study of BL-B01D1 in Patients With Multiple Solid Tumors, Including Recurrent or Metastatic Gynecological Malignancies |
|
|
| Recruiting | 1/2 | 32 | RoW | BL-B01D1 | Sichuan Baili Pharmaceutical Co., Ltd., Baili-Bio (Chengdu) Pharmaceutical Co., Ltd. | Gynecological Malignant Tumor, Solid Tumor | 06/25 | 06/25 | | |
NCT04586335: Study of CYH33 in Combination With Olaparib an Oral PARP Inhibitor in Patients With Advanced Solid Tumors. |
|
|
| Terminated | 1 | 24 | US, RoW | CYH33, Olaparib | Haihe Biopharma Co., Ltd. | Ovarian Cancer, Breast Cancer, Solid Tumor, Prostate Cancer, Endometrial Cancer | 02/23 | 02/23 | | |
KUNLUN-001, NCT06375187: Engineering Tumor Infiltrating Lymphocytes Injection (GC203 TIL) for the Treatment of Advanced Malignant Solid Tumors |
|
|
| Recruiting | 1 | 18 | RoW | Engineering Tumor Infiltrating Lymphocytes, GC203 TIL | Shanghai Juncell Therapeutics | Solid Tumor, Gynecologic Cancer, Breast Cancer, Gastrointestinal Cancer, Lung Cancer | 11/25 | 05/27 | | |
NCT06428331: A Study of SKB518 in Patients With Advanced Solid Tumors |
|
|
| Not yet recruiting | 1 | 150 | NA | SKB518 for injection, SKB518 | Sichuan Kelun Pharmaceutical Research Institute Co., Ltd. | Advanced Solid Tumors | 06/26 | 06/26 | | |
| Recruiting | 1 | 170 | RoW | SPH7485 | Shanghai Pharmaceuticals Holding Co., Ltd | Advanced Solid Tumor | 12/27 | 12/27 | | |
| Recruiting | 1 | 20 | RoW | Autologous Tumor Infiltrating Lymphocytes (C-TIL052A) Injection | Fudan University, Cellular Biomedicine Group Ltd. | Cervical Cancer | 07/25 | 07/25 | | |
NCT05952947: HRYZ-T101 Injection for HPV18 Positive Solid Tumor |
|
|
| Recruiting | 1 | 32 | RoW | HRYZ-T101 Injection, Fludarabine + Cyclophosphamide | HRYZ Biotech Co. | Cervical Cancer, Head and Neck Squamous Cell Carcinoma, Carcinoma of Vagina, Carcinoma of Penis, Anal Cancer, Carcinoma of Vulva | 12/27 | 02/28 | | |
NCT04773327: Efficacy and Safety of PEG-rhG-CSF in the Prevention of Neutropenia After Chemo in Pts With Gynecological Malignancies |
|
|
| Not yet recruiting | N/A | 150 | RoW | Mecapegfilgrastim Injection, PEG- rhg - csf | Xiaohua Wu MD | Gynecologic Malignant Tumor | 06/22 | 08/22 | | |
NCT04903665: PERformance of Multi-Cancer Early-detectIon Based on Various Biomarkers in fEmale Cancers, PERCEIVE-I |
|
|
| Active, not recruiting | N/A | 495 | RoW | Multi-cancer early detection test | Fudan University, Guangzhou Burning Rock Bioengineering Ltd | Gynecologic Cancer | 08/22 | 12/22 | | |
SHAPE, NCT01658930: Radical Versus Simple Hysterectomy and Pelvic Node Dissection With Low-risk Early Stage Cervical Cancer |
|
|
| Completed | N/A | 700 | Europe, Canada, RoW | Radical Hysterectomy + pelvic lymph node dissection, Simple hysterectomy + pelvic lymph node dissection | Canadian Cancer Trials Group, Gynecologic Cancer Intergroup (GCIG), Canadian Institutes of Health Research (CIHR), Korean Gynecologic Oncology Group, Dutch Gynecologic Oncology Group, Cancer Trials Ireland, Arbeitsgemeinschaft Gynaekologische Onkologie Austria, Belgium Gynecologic Oncology Group, Group d'Investigateurs Nationaux pour l'Etude des Cancers Ovariens, Institute of Cancer Research, United Kingdom, Shanghai Cancer Centre Deptartment of Gynecologic Oncology Fudan University, Hertzen Moscow Scientific Research Institute of Oncology, Arbeitsgemeinschaft Gynaekologische Onkologie Studiengruppe Ovarialkarzinom Germany, Institut Claudius Regaud - Institute Universitaire du Cancer de Toulouse - Oncopole | Cervical Cancer | 03/23 | 11/24 | | |
NCT06001099: PERformance of Multi-Cancer Early-detectIon Based on Various Biomarkers in fEmale Cancers, PERCEIVE-II |
|
|
| Recruiting | N/A | 2935 | RoW | | Fudan University, Guangzhou Burning Rock Dx Co., Ltd. | Gynecologic Cancer | 06/24 | 12/24 | | |
| zheng, zhong |
NCT04520074: Adjuvant Chemotherapy of Three-step Regimen in BRCA1/2 Wide Type Ovarian Cancer (ACTS-2) |
|
|
| Recruiting | 3 | 590 | RoW | Etoposide, Cyclophosphamide, Carboplatin/Cisplatin | Fudan University | Ovarian Cancer | 09/27 | 09/30 | | |
NCT05819060: The Efficacy and Safety of The Fuzuloparib Combination With Bevacizumab |
|
|
| Not yet recruiting | 2 | 44 | RoW | Fuzuloparib Combination with Bevacizumab | Fudan University | Recurrent Ovarian Cancer | 09/24 | 03/25 | | |
